Title: 213Bi (Alpha-emitter)-Antibody Targeting of Breast Cancer Metastases in the neu-N Transgenic Mouse Model
Authors: SONG H.SHAHVERDI K.HUSO D. L.ESAIAS C.FOX J.LIEDY A.ZHANG Z.REILLY R. T.APOSTOLIDIS CHRISTOSMORGENSTERN ALFREDSGOUROS G.
Citation: CANCER RESEARCH vol. 68 no. 10 p. 3873-3880
Publisher: AMER ASSOC CANCER RESEARCH
Publication Year: 2008
JRC N°: JRC45708
ISSN: 0008-5472
URI: http://publications.jrc.ec.europa.eu/repository/handle/JRC45708
DOI: 10.1158/0008-5472
Type: Articles in Journals
Abstract: Treatment failure in breast cancer is largely the failure to control metastatic dissemination. In this study, we investigated the efficacy of an antibody against the rat variant of HER-2/neu, labeled with the -particle emitter 213Bi to treat widespread metastases in a rat/neu transgenic mouse model of metastatic mammary carcinoma. The model manifests wide-spread dissemination of tumor cells leading to osteolytic bone lesions and liver metastases, common sites of clinical metastases. The maximum tolerated dose was 120 µCi of 213Bi-7.16.4. The kinetics of marrow suppression and subsequent recovery were determined. Three days after left cardiac ventricular injection of 105 rat HER-2/neu--expressing syngeneic tumor cells, neu-N mice were treated with (a) 120 µCi 213Bi-7.16.4, (b) 90 µCi 213Bi-7.16.4, (c) 120 µCi 213Bi-Rituximab (unreactive control), and (d) unlabeled 7.16.4. Treatment with 120 µCi 213Bi-7.16.4 increased median survival time to 41 days compared with 28 days for the untreated controls (P < 0.0001); corresponding median survival times for groups b, c, and d were 36 (P < 0.001), 31 (P < 0.01), and 33 (P = 0.05) days, respectively. Median survival relative to controls was not significantly improved in mice injected with 10-fold less cells or with multiple courses of treatment. We concluded that -emitter 213Bi-labeled monoclonal antibody targeting the HER-2/neu antigen was effective in treating early-stage HER-2/neu--expressing micrometastases. Analysis of the results suggests that further gains in efficacy may require higher specific activity constructs or target antigens that are more highly expressed on tumor cells.
JRC Institute:Institute for Transuranium Elements

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.